Sino-U.S. To Jointly Set Up Medical Device R&D Base In Shenzhen
This article was originally published in PharmAsia News
Executive SummaryShenzhen Institute of Advanced Technology, a branch of the Chinese Academy of Sciences, and American medical device company STI Medical Systems will jointly set up a high-level medical device R&D base in Shenzhen. The collaboration will focus on five areas: (1) STI will invest in SIAT and set up the R&D facility; (2) STI and SIAT will jointly apply for research grants from the U.S. National Science Foundation, National Institutes of Health and the U.S. FDA; (3) SIAT may send its students for internships in the U.S; (4) both organizations will incorporate their funding, technology, talent and facilities as well as research management experience; and (5) both will establish an integrated industry application laboratory and possibly a joint venture firm when future conditions are ripe. (Click here for more - Chinese Language)
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.